Phase 4 COPD Trial, Recruiting NCT07135427 Sponsor: University of Alabama at Birmingham Condition: COPD
Back to Copd

Phase 4 COPD Trial, Recruiting

NCT07135427
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who carry one copy of a specific genetic variant called the SERPINA1 Z allele (a gene change linked to a condition called Alpha-1 Antitrypsin Deficiency)
  • People who have either had no serious flare-ups of a chronic lung condition (COPD) in the past year, or who have had 2 or more serious flare-ups in the past year
  • People who have not received a pneumococcal conjugate vaccine (a specific type of pneumonia vaccine) in the last 5 years, or who have only ever received a different type of pneumonia vaccine called the pneumococcal polysaccharide vaccine

Who may not be able to join:

  • People who have received a pneumococcal conjugate vaccine within the past 5 years
  • People who have a known allergy, serious reaction, or sensitivity to pneumococcal conjugate vaccines (a specific type of pneumonia vaccine)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 2059343411

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
3 September 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Antibody response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov